Categories
Medical devices

Scope of the agreement published on June 22, 2021 for marketing authorization certificates for medical devices in Mexico

On June 22nd of this year an agreement was published, which modifies the one published on January 28th, 2020, on marketing authorization certificates through equivalence acknowledgement for authorized medications by the regulatory agencies, mentioned afterwards.

The most important modification is that in the agreement of June 22nd, Medical Devices are now included, which were not on the first edition of the agreement. It also establishes the criteria and technical requirements needed to apply for the approval through equivalence acknowledgement.

Remember that ‘medical devices’ include all items mentioned on Chapter IX of the Regulation of Healthcare Products (RIS): medical equipment, prosthetics, orthotics, functional help, diagnostic agents (IVD), odontology products, surgical material, healing material, hygiene products, and other healthcare products.

It is important to differentiate this agreement from the ones published in 2010 and 2012, since the requirements of marketing authorization certificates through equivalence acknowledgement are totally different. Though, it may be confusing because some of the regulatory agencies are the same and both agreements mention equivalence and acknowledgement. However, they are completely different topics.

The agencies acknowledged on this agreement for the marketing authorization certificate in Mexico are:

Regulatory agency:
FDA – USA
Health Canada
MHLW (Ministry of Health, Labour and Welfare) Japan, for the marketing authorization in Japan
Tests and monitoring:
PMDA (Pharmaceuticals and Medical Devices Agency), Japan
European Commission
MHRA – Medicines and Healthcare products Regulatory Agency, United Kingdom
MFDS – Ministry of Food and Drug Safety, Korea
TGA – Therapeutic Goods Administration, Australia
ANVISA – Brazil

Marketing authorization certificates protected by this agreement:

  • To apply for marketing authorization certificates of medical devices, it is required to apply in writing
  • Dossiers can be submitted in English or Spanish
  • Attention times for applications will be half than the established period
  • The established periods mentioned on Art. 179 in RIS are:
    • Class I – 30 days with affirmative ficta
    • Class II – 35 days
    • Class III – 60 days
    • With pre-verification from authorized third parties – 15 days
  • So, the longest period will be 30 days, which should be confirmed in practice.

There are some important considerations mentioned in the publication form January 28, 2020, that will not be affected by the last publication:

It will be reason to reject the application if the product is bulletined by the WHO or by any regulatory agency, or when the safety profile is not acceptable, or the risk-benefit ratio is not favorable.

Period: 30 workdays with negative ficta, one third (10 days) for administration requirement deficiency letters, two thirds (20 days) for technical requirement deficiency letters. As in any other procedure, once a deficiency letter is issued, the timeline will be suspended and resumed the next workday after an answer has been submitted.

The marketing authorization certificate holders that obtain the certificate through this ordinance are not exempt of complying with other requirements to maintain the approval, or be subject to sanitary monitoring and control. It remains an obligation to make registration renewals and variations, as with any other marketing authorization approval obtained through any other path.

If the registration in the country of origin is revoked, Cofepris must be informed within 5 workdays, as well as any changes in the safety profile or risk-benefit ratio.

The requirements to obtain the registration by this path will be published soon in this same site, please subscribe to our newsletter to be informed.

Categories
Health Regulation

Importation of health supplies without marketing authorization certificate (registration) in Mexico

Mexico has several equivalence agreements for marketing authorization regarding health supplies, which includes pharmaceuticals and medical devices, that have been published since 2010.

Their target has been to acknowledge the approval issued by other countries’ authorities, as well as the technical and legal documents that supported such authorization.

Said acknowledgement is unilateral, per equivalence, and it is not automatic; it is subject to several terms and requirements that we will be able to review on our future publications. These have the purpose of fastening the process of obtaining the marketing authorization certificate or registration in Mexico, an indispensable requirement for marketing in this nation, issued by our health authority, COFEPRIS.

Last June 22nd, the Federation’s Official Journal (DOF in Spanish) published an amendment to the equivalence agreement to obtain the marketing authorization certificate for health supplies previously published on January 28th, 2020.

One of the most important amendments were those on Section IV: “Importation of health supplies without marketing authorization certificate.”

Because of the imperious need for health services to function efficiently in Mexico, and because of the growing pandemic-related need for health supplies, COFEPRIS has given the opportunity to import health supplies without a marketing authorization certificate in Mexico. If the following terms and requirements are met:

  • COFEPRIS will directly engage with other institutions, to determine which will be the pharmaceuticals and medical devices to be imported, in order to cover the needs of health services and social security adequately and promptly.
  • Health supplies without marketing authorization certificate, can only be imported if these are meant to meet the needs and demands of public health services and social security institutions, so they are ONLY for biding and tenders, they are not for sale to private institutions.
  • Health supplies without marketing authorization certificate, must have been authorized by one of the regulatory agencies mentioned in the agreement or be pre-qualified by the WHO, or have a marketing approval from the regulatory agency for the Members of PIC/S.
  • COFEPRIS will issue the corresponding importation permits under the key: COFEPRIS-01-009-C (pharmaceuticals) and COFEPRIS-01-014-A (medical devices). If the already established requirements are met. Additionally, the following requirements must be met: proof of marketing authorization from one of the acknowledged agencies; a letter requesting adhesion to the agreement in question, and the commitment to submit the application for registration in the established timing, and last but not least: proof that the supplies are being imported for the government purchase.
  • COFEPRIS may review the status of the application for registration of the pharmaceuticals and medical devices to be imported; in case it is necessary, it will do what is needed to prevent a possible health risk of those who do not have an approval in Mexico.
  • After the first importation, there is a deadline of 10 workdays to start the registration process, which can also be started prior to the importation. In case this requirement is not met, no further importation will be approved.
  • Importers are obligated to comply with the pharmacovigilance or technovigilance, accordingly, under the current regulations (NOM’s).
  • Through the Commission of Sanitary Operation, COFEPRIS will take samples of the imported batches (pharmaceuticals) to be tested by the Commission for Analytic Control and Coverage Broadening (CAYAC) or by an authorized third party in analysis.
  • The allowed time for attending at requests for importation permits of these drugs and medical devices will be cut down to a third of their legal period (5 days). The regulatory authorities mentioned in the agreement are the following:

Drugs

  • Swiss Agency for Therapeutic Products – Swissmed,
  • European Commission,
  • Food and Drug Administration (FDA) of the United States of America,
  • Canada Health Ministry (Health Canada),
  • Therapeutic Goods Administration of Australia (TGA),
  • Reference regulatory agencies (WHO/ PAHO),
  • Prequalified products by the WHO’s Prequalification Program for Drugs and Vaccines,
  • Regulatory agencies members of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Medical Devices:

  • Food and Drug Administration (FDA) of the United States of America,
  • Canada Health Ministry (Health Canada),
  • Ministry of Health, Labor and Welfare Japan (MHLW),

Testing and inspections made by:

  • Product Development and Management Association Japan (PDMA),
  • Medicine and Healthcare products Regulatory Agency United Kingdom (MHRA),
  • Ministry of Food and Drug Safety Korea
  • Therapeutic Goods Administration of Australia (TGA),
  • Brazil Health Regulatory Agency (ANVISA)
Categories
Medical devices

Estimated Registration Times

Traditionally our MoH does not comply with the official times of registration, based on our experience (pre-COVID), we can give you an estimate from submission, of a 100% completed dossier, in Spanish, just as Cofepris expects it.

Traditional path of registration directly to Cofepris (pre-COVID timing):

  • New registration: Class IA: 1-3 months.
  • New registration: Class I and II: 6-10 months
  • New registration: Class III: 10-18 months

If the dossier is not complete, or if there is a doubt about anything, Cofepris will request additional information in a deficiency letter, called “prevention”. Cofepris provides a deathline to answer that prevention, if the information is not submitted complete and on time, the application will be cancelled, so always consider that the more complete the dossier is, the faster it will be approved, as the issuing of a prevention delays the registration time in about 4 months, plus the time you take to get the information and answer.

This is why is so important that your consultant have experience in fulfilling complete and accurate applications, so your products will be approved faster. For more information contact us.

We will be discussing in the future the updates on the regulation, to be up to date, please subscribe to our newsletter, link on the footer.

UNOPS fast track registrations.

Equivalence procedures for medical devices.

On November 18th, 2020, Cofepris published very aggressive timelines: 5 working days for registration approval for those new registrations submitted via equivalence procedures.

However, we cannot guarantee that our authorities will actually comply this timing. This approval is only for bids and government sales (UNOPS biding), and it is not applicable for private sales. If you want to sale in private market you can use or not equivalence procedures, but the registration time will be the regular one.

There are 3 recognized equivalence procedures:

  • US FDA (they require a 510k + EIR)
  • Health Canada
  • Japan

We will be discussing in the future the specific requirements for each equivalence procedure, among other updates on the regulation, to be up to date, please subscribe to our newsletter, link on the footer.

For more information about obtaining your registration in Mexico with or without equivalence procedures contact us.

Categories
Medical devices

Clases of medical devices and grouping criteria

Classes: In Mexico there are 4 classes for Medical devices:

  • IA – Low risk – there is a specific list and the device must be listed to be in this classification.
  • I – Mainly external products – not sterile, per example: hygienic products
  • II – Sterile or invasive that stays in the body or in contact with the patient for less than 30 days
  • III – Invasive that stays in the body or in contact with the patient for more than 30 days. Includes all implants. High risk products.

Classification/grouping is according to Mexican criteria and ruling, despite the classification in the country of origin.

If you have any doubt please contact us and we will help you to determine the classification for your medical devices.

Grouping criteria:

In Mexico, as in many countries, you can register a family of products together, if they comply with the grouping criteria from Cofepris, which a Grosso modo are the following.

The products to be grouped must have:

  • The same manufacturer
  • Same class (according to Mexican classification)
  • Same intention of use (final indication) and technology (new technology is new registration)
  • Same materials or formulation (same active ingredients)
  • Consider that all that can be sold apart must be registered apart (p. e. consumables, if they will be imported independently, they will need a separate registration)

Final criteria are always from Cofepris. If you have any doubts about how to group your product please contact us and we will be happy to help.

We will be discussing in the future the specific requirements for registration, among other updates on the regulation, to be up to date, please subscribe to our newsletter, link on the footer.

Categories
Medical devices

What do you need for selling medical devices in Mexico?

If you are a medical devices manufacturer and are interested in selling / importing your medical devices to Mexico, then you want to continue reading.

Medical devices are described under the General Health Law in Mexico and includes the following products:

– Medical equipment

– Prothesis, orthosis and functional aids

– Reactives, diagnostic agents and IVDs

– Odonthological supplies

– Surgical and healing supplies (medical materials)

– Hygienical products

Medical devices require a registration (Marketing authorization) that is valid for 5 years and can be renewed, and sometimes requires importation permit after registration for each importation.

In order to register a medical device in Mexico, you need to comply the following in order to be eligible to be a registration holder in Mexico, and make a registration application:

  1. You need to be a legally established company in Mexico with a legal representative with permanent residence in Mexico
  2. You need to have an operational warehouse with a quality system (SOPs) – notified in MoH, The Mexican Pharmacopeia describes the infrastructure you need for a health supplies warehouse, and basically it needs to be an independent warehouse from other companies and different classification of products.
  3. Also you need a Sanitary responsible also called technical director that can be a Pharmacist, biomedical engineer or chemist – notified in MoH
  4. Finally you need to have a technovigilance unit with a technovigilance responsible – notified in MoH

If you are not ready to develop your own infrastructure, Rafconsulting can act as your Mexican Registration Holder (MRH) for your registrations in Mexico. Please contact us for more information.

Once you comply with the company’s requirements to register medical devices, then you can proceed to the registration application for your medical device:

The general requirements for registration are the following:

  1. Free sale certificate (FSC) issued by the Health Authority from the Country of Origin or clinical trials performed in Mexico. Legalized original.
  2. GMP certificate or ISO 13485 for every facility involved in the process (Manufacturing, sterilization, packaging, etc.) Legalized original
  3. Representation letters or Power of attorney naming holder and distributors (issued by manufacturer) Legalized original.
  4. Technical dossier: must document every step from design, materials, manufacturing, finished product, stabilities, performance, etc. You need to demonstate quality, safety and efficacy, and detailed evidence is required.
  5. Original Certificate of Analysis or Conformance.
  6. Everything must be submitted in Spanish and organized according to Cofepris Criteria.

 

In Rafconsulting we will be happy to help you determine the requirements for your specific product, we can help you with all that you need to register, import and sale your medical devices in Mexico, please contact us for more information.

We will be discussing in the future the specific requirements for registrations, among other updates on the regulation, to be up to date, please subscribe to our newsletter, link on the footer.

Categories
Facilities

Impact of modifications proposed by COFEPRIS to current medical devices regulation

Last April 7th, 2021, Cofepris proposed to the applicable authority (CONAMER) a draft for changing current “Reglamento de Insumos para la Salud” (RIS) that is where the main regulation for medical devices and Pharmaceuticals is defined, besides others. The draft was accepted past May 12th, and now we are expecting its publication when it will become official. However, it is still subject to some changes.

 

We will comment now the main modifications that affects registrations of medical devices. Pharmaceuticals will be reviewed in a separate publication.

 

  1. Application and variation for registrations:

Cofepris in an aim of being aligned with international practices, is proposing the acceptance of the dossiers in English or Spanish. We foresee a considerable advantage in the timing for preparation of a dossier for submission, as well as an important reduction in costs, avoiding translations. The reduction could be applied by manufacturers for new product registrations and to increase the offer of medical devices in the Mexican market.

 

However, Cofepris has now the challenge of hiring and training a team of specialized and bilingual personnel, in order to review English dossiers properly.

 

Talking of registration variations, the total timeline for using packaging materials with previous texts, is now being included in the registrations (before it was half the time and you had to make up to 3 extensions) avoiding further requests that will release Cofepris for quite some submissions.

 

In the case of rights transferals, now it will just be the right transferal submission without variation, which implies some changes in the organization of the dossier and inclusion of less documents.

 

  1. Changes in registrations renewals:

The purpose of the renewals is no more to verify that the registered conditions are complied. Therefore, the renewal is simplified: no more labels, certificates of analysis nor GMP certificates for local manufacturers, in the case of foreign manufacturers, the requirement to provide GMP/ISO certificates is maintained.

 

Once the first renewal of the registration is approved, the validity of the registration is undefined, which means that the registration will have no expiry date, so no further renewals. Unless that the technovigilance report indicates safety issues that should be observed, in which case Cofepris will request and additional renewal of the registration, we will know upon approval within the registration official letter.

 

The timeline for submitting the renewal now changes from 150 to 270 natural days before the expiry date of the registration. The timeline for Cofepris to answer the renewal will be now reduced to 120 days, in case they do not answer the renewal is considered authorized, however, Cofepris must issue the official registration letter in any case.

 

Application timeline after publication:

This regulation will become effective next day of its publication. Cofepris will have then 90 days to publish any adequation to current regulations, per example the Technovigilance norm. As happens with all Mexican regulations the application of these changes will not be retroactive. And no-one knows for sure when these regulations are being published, but it might be soon.

 

Conclusions:

The proposed modifications, in addition to simplify some submissions that are not very relevant (for example: the extensions of timelines to use previous packaging materials), and the harmonization with international practices regularly applied by Recognized Regulatory Agencies, and the substantial reduction of registrations renewals, can just have a strong and positive impact on the workload and costs, for Cofepris, as well as the regulatory departments of the manufacturers/distributors.

 

We can only hope that all these measures help to speed up the resolutions from Cofepris, including those delayed submissions that counts about 8000* at this point of time, as indicated in the regulation papers. The outcome is expected to be positive for both sides.

 

In addition, the tone of the proposal looks like an attempt from the authority to open up to the industry with regards of empathy and to reestablish a communication path, including a vote of confidence in which it is recognized that the private sector has the intention and will to comply with regulations, at least in its great majority.

 

Therefore, the authority can now reduce requirements to a reasonable level, without incurring in risks for the people. We think that it is now understood that overregulation only causes an increase in costs and resources for the industry and an overload for the authority that becomes complicated to solve.

 

* Number of delayed submissions apparently includes all types of submissions.